Sofosvel is the global first generic oral tablet for pan-genotypic Chronic Hepatitis C treatment. This combination (Sofosbuvir 400 mg + Valpatasvir 100 mg) drug has been approved by US FDA & European Commission for treatment of patients with all genotypic Chronic Hepatitis C virus infection. Sofosvel is used without cirrhosis or with compensated cirrhosis, and patients with advanced cirrhosis (Decompensated).
Sofosvel is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infections
• With or without cirrhosis or with compensated cirrhosis
• With decompensated cirrhosis for use in combination with Ribavirin
Product Name : Sofosvel
Generic Name : Sofosbuvir 400mg + Velpatasvir 100 mg
Formulation : Solid dosage form(Tablet)
Available Pack Size : 1×6’s
Available Strengths : 400mg+ 100mg
Categories : Anti-viral, Biotech Products, Drugs to treat Hepatitis
Manufacturer : Beacon Pharmaceuticals Ltd.